Gln-1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: GNL1

NCBI ID: G2794

GNL1

Gln-1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Gln-1 (GNL1) is a protein that is expressed in various tissues of the human body, including the brain, heart, and pancreas. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a crucial role in cellular signaling. GPCRs are involved in many different signaling pathways, including sensory perception, neurotransmission, and hormone signaling.

Gln-1 has been identified as a potential drug target in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for small molecule inhibitors. In this article, we will discuss the biology of Gnl1, its potential as a drug target, and the current research in this field.

Biochemistry and Structure

Gln-1 is a 21-kDa protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is composed of a single transmembrane alpha helix, which is responsible for the protein's stability and functions as a receptor . The transmembrane domain is composed of a single transmembrane伪-helix and a cytoplasmic tail. The intracellular domain is composed of a single transmembrane尾-sheet and a cytoplasmic tail.

Gln-1 has a unique fold, with a conserved N-terminal region that is involved in the formation of a transmembrane assembly complex. The N-terminal region contains a single potential G protein-coupled receptor (GPCR) domain, which is responsible for the protein's sensitivity to GPCR inhibitors. The transmembrane domain is composed of a single 伪-helix, which is responsible for the protein's stability and the formation of the transmembrane assembly complex. The intracellular domain is composed of a single 尾-sheet, which is responsible for the protein's stability and localization to the endoplasmic reticulum (ER).

Gln-1 is a glycoprotein, which means that it consists of a protein that is covalently bound to a glycine molecule. This gives the protein its name and its structure is similar to that of other glycoproteins, such as albumin and globulin.

Function

Gln-1 is involved in a wide range of physiological processes in the human body, including sensory perception, neurotransmission, and hormone signaling. Its function is closely tied to its role as a GPCR receptor.

In sensory perception, Gln-1 is involved in the development of pain signals and their integration into the central nervous system (CNS). Gln-1 is also involved in the regulation of neurotransmitter release from neurons, which is critical for the perception of pain , anxiety, and other sensory stimuli.

In neurotransmission, Gln-1 is involved in the regulation of neurotransmitter release from neurons and glial cells. Glycine, which is a ligand for Gln-1, can modulate the activity of GPCR-coupled receptors, including those that transmit neurotransmitters.

In hormone signaling, Gln-1 is involved in the regulation of hormone secretion from the endocrine system. GPCR-coupled receptors are involved in the regulation of hormone secretion from the endocrine system, and Gln-1 is one of the proteins that regulates this process..

Drug Development

Gln-1 has

Protein Name: G Protein Nucleolar 1 (putative)

Functions: Possible regulatory or functional link with the histocompatibility cluster

The "GNL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets